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Abstract: Extracellular vesicles (EVs) are involved in inter-cellular communication and their cargo
may provide prognostic/diagnostic biomarkers. To discover EV-associated biomarkers for Multiple
Sclerosis (MS), we used an immune marker array to identify surface proteins on circulating EVs
that differ between MS patients and controls (n = 3 each). We identified toll-like receptor-3
(TLR3) as a potential target for further validation. We utilized prospectively collected serum
from relapsing-remitting MS patients (n = 18) and controls (n = 16) and confirmed lower concentration
of TLR3 and higher concentration of mechanistically related TLR4 in MS EVs compared to controls.
Future studies may further evaluate the utility of EV-associated TLRs as MS biomarkers and uncover
their mechanistic significance.
Keywords: multiple sclerosis; extracellular vesicles; TLR3; TLR4; innate immunity
1. Introduction
Multiple sclerosis is a chronic autoimmune disorder of the CNS with inflammatory and
neurodegenerative components [1]. There is a need for both diagnostic and prognostic biomarkers
to help improve the management of this heterogenous disorder. Extracellular vesicles (EVs) are
membranous nanoparticles produced by all cells and contain cargo of nucleic acids (RNA, DNA),
proteins and metabolites, whereas their surface is replete with immune mediators. Based on their cell of
origin and cargo, EVs can have a variety of functions including cellular homeostasis and inter-cellular
communication [2,3]. In neurological disorders such as Alzheimer’s disease (AD), Parkinson Disease
(PD), and Neuro-HIV, the contents of EVs have been demonstrated to provide diagnostic, prognostic
and therapeutic response biomarkers [4–6].
Alterations in EVs were described in MS almost two decades ago [7]. Previous studies in MS have
largely examined the miRNA content of circulating EVs and have demonstrated significant alterations
in miRNA profiles and relationships to disease course and treatment response [8–10]. Specific miRNA
have also been implicated in potentially pathogenic effects on the immune system in MS [11]. MS EVs
also appear to differ from controls in their lipid content [12,13]. Only one previous study evaluated
the protein cargo of circulating EVs and noted alterations in myelin associated proteins [14]. While
alterations in both the adaptive and innate immune system play critical roles in MS, the expression of
immune markers has not been evaluated in MS EVs.
In this study, we first employed an extensively utilized EV Array targeting surface markers
including immune mediators [15,16] and identified potential MS biomarker targets that were
subsequently validated in a larger cohort of MS and control participants using targeted immunoassays.
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We demonstrated lower toll-like receptor 3 (TLR3) concentration and higher concentration of the
mechanistically related TLR4 in circulating EVs of MS patients as compared to healthy controls.
2. Materials and Methods
2.1. Participants, Standard Protocol Approvals, and Patient Consents
We enrolled patients with Relapsing Remitting (RR) MS from the Johns Hopkins MS Center and
age-, sex-, and race-matched controls. The protocol for this study was approved by the Johns Hopkins
Institutional Review Board. All participants provided informed consent. Demographic and disease
related information was collected from all participants. Participants underwent phlebotomy and blood
was collected in red-top tubes and allowed to clot for 30 min, followed by centrifugation at 3000 RPM
for 10 min to separate serum. Serum was then divided into 1.0 mL aliquots, which were stored at
−80 ◦C until the time of EV isolation.
2.2. Isolation of Extracellular Vesicles
Serum samples were thawed on ice and 500 µL were immediately subjected to commercially
available nanoparticle precipitation solution Exoquick® (System Biosciences, Mountainview, CA,
U.S.) to isolate total EVs. First, the total EVs were sedimented according to the manufacturer’s
instructions, and then resuspended in 200 µL of ultra-pure distilled water supplemented with protease
and phosphatase inhibitors. 10 µL of intact EVs suspension were used for the determination of
particle concentration and diameter using nanoparticle tracking analysis (NTA) (Nanosight NS500,
Malvern, Amesbury, UK) and (for 6 samples) 10 µL of intact EVs were used for the EV Array. For the
NTA, the particle concentration in function of particle diameter was averaged from five 20-s videos
captured using the following settings: scattering camera level, 15; slider shutter, 1206; slider gain,
366; detection threshold, 3; and sample dilution ranging from 1:100 to 1:200 providing a range of
50–250 particles/frame. The remaining volume was mixed with 300 µL of MPER lysis buffer (Thermo
Scientific, Grand Island, NY, U.S.) supplemented with protease (cOmplete ULTRA Tablets, Roche,
Millipore Sigma, St. Louis, MO, U.S.) and phosphatase (HALT Phosphatase Inhibitor Cocktail, Thermo
Fisher Scientific, Cincinnati, OH, U.S.) inhibitors and was subjected to two freeze-thaw cycles to
generate lysates for downstream ELISA.
2.3. EV Array
The EV Array was developed based on the technology of protein microarray to phenotype
serum-derived EVs (optimized for small EVs/exosomes) for multiple antigens without any enrichment
or purification prior to analysis [16]. Micro-sized spots of 40 different capturing antibodies (200 µg/mL)
against known EV surface antigens were printed on standard epoxysilane-coated microarray slides
(SCHOTT Nexterion, Germany) using a SpotBot® Extreme Protein Edition Microarray Printer (ArrayIt
Corporation, CA, U.S.). The EV Array was performed as described by Jørgensen et al., 2013 with
modifications. In short, the microarray slides were initially blocked (50 mM ethanolamine, 100 mM
Tris, 0.1% SDS, pH 9.0) prior to incubation with 10 µL serum sample diluted (1:10) in wash-buffer
(PBS/0.05% Tween®20). The incubation was performed in Multi-Well Hybridization Cassettes (ArrayIt
Corporation) at RT for two h, followed by overnight incubation at 4 ◦C. A cocktail of biotinylated
detection antibodies (anti-human-CD9, -CD63, and -CD81, Ancell, MN, U.S.) diluted 1:1500 was
used to detect retained EVs using Cy5-labelled streptavidin (Life Technologies, MA, USA) diluted
1:1500. Scanning and spot detection was performed as previously described (Bæk and Jørgensen,
2017). The data from the EV Array were compared as raw values and also normalized by the total
number of particles present in 10 µL (measured by NTA). Afterwards, the data were log2 transformed;
therefore, biomarker differences can be considered as “per EV”. The relation between positive and
negative controls was determined to be >0.98, suggesting an acceptable level of background noise for
all measured markers.
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2.4. Measurement of Markers in EVs
EV Array results for proteins differentially expressed in MS patients and controls were validated
by colorimetric ELISA using total EV lysates (TLR3: cat. no. ab131557, Abcam, Cambridge, MA, U.S.;
TLR4: cat. no. LS-F3675, LSBio, Seattle, WA, U.S.). First, we determined the optimal sample dilution
providing signals within the linear range of each standard curve using a subset of samples. Samples
were assessed either undiluted or diluted in 1:1 and 1:4 ratios using the buffers provided. Based
on results, we proceeded to evaluate TLR3 and TLR4 protein levels in the entire relapsing-remitting
multiple sclerosis (RRMS) discovery cohort using samples diluted in a 1:1 ratio. Each sample was
assessed in duplicate obtaining mean coefficients of variance of 4.6% for TLR3 and 3.0% for TLR4.
Protein concentration was extrapolated from raw absorbances using the trendline equations of standard
curves from which the limit of detection (LoD) and lowest limit of quantification (LLoQ) were
determined. The LoD was defined as the mean signal of the diluent blank plus 2.5 times its standard
deviation, whereas the LLoQ was determined by the standard solution with signal above the LoD,
CV among duplicates lower than 20%, and recovery between 80% and <120%. Samples with protein
concentration below the LLoQ but with signal above the LoD and CV <15% were assigned the
plate LLoQ.
2.5. Statistical Analysis
We compared groups for demographic characteristics using either a t-test for continuous or a
chi-square test for categorical variables. We compared concentrations of markers in the EV Array using
a Welch’s t-test and performed correction for false discovery using a Benjamini-Hochberg procedure
setting the false discovery rate at 0.2. For the TLR3 and TLR4 concentrations, we used a Mann-Whitney
U-test to compare groups, given the sample size. We considered a p-value of <0.05 as significant.
For the individual marker comparisons, we also excluded outlier values (defined as 1.5 times the
interquartile range [IQR]) above the third quartile or below the first quartile—this resulted in removal
of two observations in each group for TLR3 and two observations in the healthy control (HC) group
and one in the MS group for TLR4.
3. Results
3.1. Study Cohort
We enrolled 18 RRMS patients and 16 controls in the study. The demographic and disease
characteristics are summarized in Table 1. There were no significant group differences in age, sex,
or race. The majority of RRMS patients were either untreated or on an injectable disease-modifying
therapy (interferon-beta or glatiramer acetate), however, two participants were receiving natalizumab.
Table 1. Demographic and disease characteristics of participants.
Characteristic RRMS HC
Number 18 16
Age, years (mean ± SD) 43.9 ± 10.8 39.4 ± 8.9
Female sex, n (%) 13 (72.2) 11 (68.5)
Caucasian Race, n (%) 16 (88.9) 14 (87.5)
Expanded Disability Status Scale (EDSS), median (IQR) 2.0 (1.5) -
Disease duration, years (mean ± SD) 9.8 ± 6.2 -
Current disease-modifying therapy
None 9 -
Glatiramer acetate 4 -
Interferon beta 3 -
Natalizumab 2 -
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3.2. EV Array Identified Lower Levels of Multiple Surface Markers in MS Compared to Controls
In an initial experiment involving a small set of MS patients and controls (n = 3 each), we utilized
the “EV Array” to detect the presence of various surface markers and immune mediators on intact
serum EVs. Of the three MS patients chosen for the EV array, one was untreated, one was on glatiramer
acetate, and the third was on natalizumab. We noted a reduction or trend for several markers,
with significant differences listed in Table 2. We chose TLR3 as a target for further validation since it
was one of the most differentially expressed markers and has been known to play important roles in
innate immunity [17]. For mechanistic context, we decided to also assess the abundance of a TLR4,
a receptor not included in the EV Array that is also associated with innate immunity and implicated in
several inflammatory disorders, including MS [18–20], often with opposing activity to TLR3.
Table 2. Summary of comparisons of extracellular vesicle (EV) array markers between Multiple Sclerosis
(MS) patients and controls.
MS
Rel. Intensity (log2
Mean ± SEM)
n = 3
Control
Rel. Intensity (log2
Mean ± SEM)
n = 3
Total Serum EVs
(p Values)
Total Serum EVs Normalized by EV
Concentration by (Nanoparticle
Tracking Analysis) NTA
(p Values)
CD171 0.35 ± 0.07 1.97 ± 0.24 0.003 0.004
TLR3 3.49 ± 0.87 7.55 ± 0.35 0.011 0.011
Annexin V 0.93 ± 0.63 5.52 ± 0.83 0.012 0.012
CD83 1.46 ± 0.49 4.83 ± 0.64 0.014 0.016
CD3 3.72 ± 0.51 6.75 ± 0.54 0.015 0.018
CD45RA 0.20 ± 0.20 2.94 ± 0.64 0.015 0.018
LAMP-1 0.07 ± 0.07 3.03 ± 0.74 0.016 0.018
a-SYN 0.72 ± 0.43 3.52 ± 0.57 0.017 0.021
CD45RO 1.11 ± 0.51 4.31 ± 0.76 0.025 0.028
CD25 3.12 ± 0.88 6.60 ± 0.59 0.031 0.032
CHRM4 1.45 ± 0.39 3.40 ± 0.49 0.036 0.039
CD197 0.67 ± 0.47 3.85 ± 0.91 0.037 0.04
ADBB2 2.82 ± 0.23 4.38 ± 0.46 0.037 0.04
TSG101 0.07 ± 0.07 2.26 ± 0.73 0.041 0.044
TGFb1 1.93 ± 0.43 4.80 ± 0.85 0.04 0.046
CD206 1.68 ± 1.07 5.66 ± 0.89 0.046 0.046
Alix 1.26 ± 0.64 4.74 ± 0.96 0.039 0.041
HLA ABC 0.16 ± 0.16 3.05 ± 1.38 0.106 0.11
CD8a 0.00 ± 0.00 1.66 ± 0.83 0.118 0.117
CD56 0.00 ± 0.00 1.38 ± 0.69 0.118 0.118
Fas L 0.00 ± 0.00 1.89 ± 0.96 0.118 0.123
TNF RII 0.00 ± 0.00 2.15 ± 1.20 0.147 0.152
TRAIL 0.00 ± 0.00 1.90 ± 1.07 0.151 0.155
CD19 0.00 ± 0.00 1.88 ± 1.10 0.162 0.167
CD45 0.06 ± 0.06 2.25 ± 1.29 0.164 0.17
CD14 0.00 ± 0.00 2.13 ± 1.27 0.169 0.174
LAMP2 0.00 ± 0.00 1.94 ± 1.21 0.183 0.188
CD106 0.00 ± 0.00 1.77 ± 1.12 0.187 0.193
TNF RI 0.30 ± 0.30 2.12 ± 1.15 0.191 0.199
Hsp90 0.00 ± 0.00 1.86 ± 1.23 0.203 0.208
CD4 0.14 ± 0.14 1.62 ± 1.02 0.226 0.233
ICAM-1 0.00 ± 0.00 1.53 ± 1.21 0.277 0.281
CD28 0.67 ± 0.67 2.44 ± 1.36 0.309 0.324
Apo E 0.56 ± 0.56 2.08 ± 1.27 0.337 0.351
Flotillin-1 0.96 ± 0.53 1.91 ± 0.96 0.431 0.435
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Table 2. Cont.
MS
Rel. Intensity (log2
Mean ± SEM)
n = 3
Control
Rel. Intensity (log2
Mean ± SEM)
n = 3
Total Serum EVs
(p Values)
Total Serum EVs Normalized by EV
Concentration by (Nanoparticle
Tracking Analysis) NTA
(p Values)
APP 0.00 ± 0.00 0.00 ± 0.00 nd nd
Hsp70 0.00 ± 0.00 0.00 ± 0.00 nd nd
General EV surface markers
CD81 2.27 ± 0.78 3.95 ± 0.65 0.171 0.167
CD9 2.11 ± 0.17 3.32 ± 0.71 0.172 0.187
CD63 0.32 ± 0.32 1.79 ± 1.25 0.318 0.322
Summary of p-values from unpaired t-tests. Green indicate significant differences between controls and MS patients
after Benjamini-Hochberg procedure for multiple comparisons using a false discovery rate at 20%.
3.3. TLR3 and TLR4 Levels Are Altered in MS Patient EVs
Next, we isolated EVs from serum samples from the entire cohort and performed quantification
of TLR3 in lyzed total EVs. Confirming the EV Array results, we noted reduced levels of TLR3 in
MS patient EVs compared to controls (Figure 1A). We also measured TLR4 and noted higher TLR4
levels in MS patient EVs compared to controls (Figure 1B). We also calculated the ratio of TLR3:TLR4
concentration and noted that the ratio was significantly lower in MS patients compared to controls
(Figure 1C).
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Figure 1. Toll-like receptor-3 (TLR3) is reduced and TLR4 is increased in EVs from MS patients
compared to controls. We compared the levels of TLR3 and TLR4 in EVs isolated from MS patient
serum. (A) We noted reduced concentration of TLR3 in EVs from the MS group (n = 18) compared
to controls (n = 16). (B) We also noted increased concentration of TLR4 in EVs from the MS group
compared to controls. (C) The ratio of TLR3 to TLR4 in EVs was also reduced in the MS group compared
to controls. All comparisons were made using a Mann-Whitney U test.
Since, we had patients with varying treatment status, to exclude an effect of treatment on the
results of TLR3/4 levels in EVs, we performed a sensitivity analyses by comparing levels of TLR3 in
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EVs between MS patients grouped based on treatment status (either on a disease modifying treatment
or no DMT) and HCs. We noted that both MS sub-groups had significantly lower levels compared to
healthy controls (no DMT-p = 0.031, on DMT-p = 0.023).
There was no significant difference in EV concentration by NTA between the two groups (Figure 2A).
The size characteristics of the isolated EVs as analyzed by NTA also appeared similar between the two
groups (Figure 2B).
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4. Discussion
This study utilized a prospectively collected cohort of RRMS patients and controls to discover
and validate an alteration in the concentrations of innate immunity-related molecules—TLR3 and
TLR4—-in circulating EVs of MS patients. This novel finding indicates the potential role of circulating
EVs as a platform for biomarker discovery in MS and also suggests the need to further explore the role
of TLRs and innate immunity in MS.
TLRs are pattern recognition receptors that are expressed either on the cell surface or intra-cellularly
and sense characteristic molecules associated with pathogens such as bacteria, viruses, or fungi [21].
While the role of TLRs in MS and experimental autoimmune encephalomyelitis (EAE) has received
significant attention, there are conflicting data between animal and human studies for several TLRs [17].
TLRs are expressed on both immune cells and several non-immune cells (including all cell types in
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the central nervous system). TLR3 is localized intra-cellularly and can sense nucleic acids and signal
through the TIR-domain-containing adapter-inducing interferon-beta (TRIF)-dependent pathway to
increase expression of type I interferons [21]. In mouse models, TLR3 activation appeared to exert
protective effects in EAE through enhanced endogenous interferon-beta production and reduced
production of Th17 cells [17,22,23]. In a human study utilizing peripheral-blood mononuclear cells
from progressive and benign MS patients, stimulation of TLR3 led to increased inflammatory cytokine
production in progressive MS patients but upregulation of anti-inflammatory genes in benign MS
patients, suggesting a potential protective role in a subset of MS patients [24].
TLR4 is expressed on the cell surface, interacts with lipopeptides and can signal through the
Myeloid differentiation primary response protein 88 (MyD88) and TRIF pathways [21]. There has been
contradictory data regarding whether TLR4 activation is protective or harmful in EAE. In human studies,
increased TLR4 and high-mobility group protein B1 (HMGB1) (a TLR4 agonist) levels were found in
cerebrospinal fluid (CSF) and stimulation of microglia and macrophages with lipopolysaccharide (LPS)
led to increased production of inflammatory cytokines [17,25].
While all of the aforementioned studies relate to TLR function within cells, the role of TLRs in
EVs has not been studied, and it is unclear whether altered TLR levels in the EV compartment have
any physiological relevance beyond potentially identifying an imbalance in the cellular compartment.
Thus, the altered balance of TLR3 and TLR4 in EVs may represent an altered balance of innate immune
signaling processes that could be relevant to the pathogenesis of the disease.
The limitations of our study include a cross sectional design, which precluded us from studying
the relationship between levels of TLR3/4 and disease activity; the fact that patients were on variable
MS disease-modifying treatments; and a relatively small size. Moreover, this study used total serum
EVs that have variable cellular origins; therefore, effects cannot be attributed to any particular cell type
but rather reflect organismal-level abnormalities in innate immunity. The main strength of this study
was its design that included an unbiased assay that was used to identify candidate biomarkers in a
smaller cohort, followed by the use of a targeted assay in a larger cohort.
Future studies with larger sample size, prospective longitudinal design and a more comprehensive
panel of TLR molecules could help further define and validate the potential role of EV TLR expression
as biomarkers for diagnosis and prognosis in MS. In addition, mechanistic studies involving EVs from
MS patients are required to uncover the mechanistic significance of these biomarkers.
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